ANTICOV Trial Finds Nitazoxanide/Ciclesonide Drug Combination Does Not Reduce Hospitalisation Risk in Patients With Mild COVID-19
, News, ANTICOV, NCT04920838, Feb 2022
RCT with 591 nitazoxanide/ciclesonide and 557 paracetamol patients, up to 7 days from onset, showing higher progression, without statistical significance.
|
risk of progression, 104.3% higher, RR 2.04, p = 0.09, treatment 16 of 591 (2.7%), control 7 of 557 (1.3%), adjusted per study, odds ratio converted to relative risk, SpO2 ≤93 or death, day 21, Table 13.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
ANTICOV et al., 28 Feb 2022, Randomized Controlled Trial, multiple countries, preprint, 1 author, this trial compares with another treatment - results may be better when compared to placebo, this trial uses multiple treatments in the treatment arm (combined with ciclesonide) - results of individual treatments may vary, trial NCT04920838 (history) (ANTICOV).